AMS •
Healthcare •
Biotechnology •
Quote as of 08/07/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeAMS
Market Capitalization1,631.88 mln
Float40.94 mln
Earnings Date08/10/2026
EPS
7.41
Strong
P / E
3.15
Deeply undervalued
Piotroski F-Score
6
/ 9
Solid
Beneish M-Score
0.58
Highly suspicious
1-Year Forecast
30.27
Strong upside
Relative Strength
5
/ 100
Severely lagging
Business Description
Lakefront Biotherapeutics NV is a Belgian biotech company founded in 1999 and headquartered in Mechelen, focused on developing new treatments for cancer and immune system diseases across the US and Europe. The company is advancing several drug candidates through clinical trials, including therapies for conditions such as lupus, lymphoma, and multiple myeloma, with two of its cancer treatments produced directly at the point of patient care. Lakefront works in partnership with Gilead Sciences and was previously known as Galapagos NV before changing its name in May 2026.
